NCT05155579: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- State
- Completed
- Phase
- Phase 1
- People
- 594 taking part
- Started
- 14 May 2022
- Primary completion
- 27 May 2025
- Arms
- Group 1b, 2b and 3b, Group 4a, Group 4c, Group 5a, Group 6a, Group 6b
- Results
- None posted
- 13 Dec 2021: Trial registered
- 14 May 2022: Trial started
- 27 May 2025: Trial completed